2025-12-31 - Analysis Report
Okay, here's a comprehensive analysis of Northrop Grumman (NOC) based on the provided data.

**1. Return Rate Comparison**

*   **Company Overview:** Northrop Grumman Corp. is a global aerospace and defense technology company.
*   **NOC Cumulative Return:** 49.08%
*   **VOO (S&P 500) Cumulative Return:** 102.21%
*   **Divergence:** -53.4%
*   **Relative Divergence:** 5.2%

**Analysis:** NOC has significantly underperformed the S&P 500 (VOO) over the period examined. The divergence of -53.4% indicates a substantial difference in returns. The relative divergence of 5.2% suggests that the current divergence is near the lower end of its historical range, indicating it has performed slightly better recently.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD     | Alpha   | Beta   | Cap(B) |
|------------|----------|---------|---------|--------|--------|
| 2015-2017  | 46.0%    | 65.6%   | 17.0%   | 0.0    | 43.9   |
| 2016-2018  | -2.0%    | 74.3%   | -17.0%  | 0.0    | 35.1   |
| 2017-2019  | 17.0%    | 79.2%   | -5.0%   | 0.9    | 49.2   |
| 2018-2020  | -28.0%   | 79.9%   | -52.0%  | 0.8    | 43.6   |
| 2019-2021  | 43.0%    | 79.9%   | -4.0%   | 0.8    | 55.4   |
| 2020-2022  | 18.0%    | 79.9%   | 19.0%   | 0.3    | 78.1   |
| 2021-2023  | 24.0%    | 82.7%   | 23.0%   | 0.2    | 67.0   |
| 2022-2024  | -15.0%   | 82.7%   | -36.0%  | 0.2    | 67.2   |
| 2023-2025  | -1.0%    | 82.1%   | -68.0%  | 0.1    | 82.3   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows fluctuating performance, with some periods of strong growth and others of decline. Recent periods (2022-2025) show negative or near-zero growth.
*   **MDD:** The Maximum Drawdown (MDD) indicates significant potential losses.  The consistently high MDD values suggest substantial risk.
*   **Alpha:** Alpha measures the stock's performance relative to a benchmark, with a positive alpha indicating outperformance.  NOC has periods of both positive and negative alpha, with recent periods showing significantly negative alpha, indicating underperformance compared to its benchmark.
*   **Beta:** Beta measures the stock's volatility relative to the market. NOC's Beta has been low recently (0.1-0.3), suggesting lower volatility than the overall market. However, the Beta was as high as 0.9 in some years.
*   **Cap(B):** Capitalization shows the company's overall size in Billions.

**2. Recent Stock Price Fluctuations**

*   **Current Price:** 574.57
*   **Previous Close:** 577.78
*   **Change:** -0.56
*   **5-day SMA:** 578.426
*   **20-day SMA:** 565.1835
*   **60-day SMA:** 578.9707

**Analysis:** The current price is slightly below the previous close, indicating a small recent dip. The 5-day SMA is above the 20-day SMA, suggesting a short-term upward trend. The 20-day SMA is below the 60-day SMA, suggesting a longer-term downward trend. The price hovering between the moving averages suggests a period of consolidation or potential uncertainty.

**3. RSI, PPO, and Other Indicators**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 64.59
*   **PPO:** 0.37
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Dividend_2.31 Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 0.5 (+) (Short-term increase)
*   **Expected Return (%):** -158.8

**Analysis:**

*   **MRI:** Despite the underperformance, the MRI suggests a "High Investment Recommended" rating.  This seems contradictory and warrants further investigation. It's important to understand the basis of this MRI calculation.
*   **RSI:** An RSI of 64.59 indicates the stock is approaching overbought territory (above 70).
*   **PPO:** A PPO of 0.37 is relatively low, suggesting the recent uptrend isn't particularly strong.
*   **Hybrid Signal:** The signal suggests buying 100% with 0% cash, suggesting confidence.
*   **Recent relative divergence change:** Suggests a slight recent uptrend, but needs to be viewed in the context of the longer-term underperformance.
*   **Expected Return:** The very high negative expected return indicates a highly pessimistic outlook. This is an extreme figure that requires careful scrutiny.

**4. Recent News & Significant Events**

*   **Rating Downgrade:** A Seeking Alpha article mentions an argument for buying at undervaluation despite a rating downgrade.
*   **Recent Pullback:** A Yahoo Finance article assesses the value after a recent 5% pullback.
*   **Implied Volatility Surge:** A Nasdaq article highlights a surge in implied volatility for Northrop Grumman stock options.
*   **Insider Sale:** Quiver Quantitative reports an insider sale by a CVP & Pres. Mission Systems.
*   **Investment Outlook:** ts2.tech provides the latest news, price targets, and investment outlook.
*   **Chart Analysis:** DailyForex suggests more gains ahead.

**Analysis:**

The news is mixed. A rating downgrade and insider selling are negative signals. However, the discussion of undervaluation, assessment after a pullback, and a chart analysis suggesting gains could indicate a potential buying opportunity for some investors. The surge in implied volatility suggests increased uncertainty or anticipation of significant price movements.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 2.04 (~Buy)
*   **Opinions:** 21
*   **Target Price (avg/high/low):** 662.68 / 770.00 / 533.00

**Analysis:** Analyst consensus is a "Buy" with a mean rating indicating a generally positive outlook. The average target price of $662.68 suggests potential upside from the current price of $574.57. However, a low target price of $533.00 indicates that some analysts are less optimistic.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue    |
|------------|------|-------------|
| 2025-10-21 | 7.69 | 10.42 B$    |
| 2025-07-22 | 8.17 | 10.35 B$    |
| 2025-04-22 | 3.33 | 9.47 B$     |
| 2024-10-24 | 7.02 | 10.00 B$    |
| 2025-10-21 | 7.02 | 10.00 B$    |

**Analysis:** The company's EPS has fluctuated. The revenue is generally stable but shows some variability. The recent EPS of 7.69 is reasonable, however, there is an identical date for the earnings data listed.

**6. Financial Information**

Revenue and Profitability:

| Quarter | Revenue   | Profit Margin |
|---------|-----------|---------------|
| 2025-09-30 | $10.42B  | 21.37%       |
| 2025-06-30 | $10.35B  | 21.35%       |
| 2025-03-31 | $9.47B   | 16.69%       |
| 2024-12-31 | $10.69B  | 18.08%       |
| 2024-09-30 | $10.00B  | 21.07%       |

Capital and Profitability:

| Quarter | Equity    | ROE   |
|---------|-----------|-------|
| 2025-09-30 | $15.99B  | 6.88%  |
| 2025-06-30 | $15.47B  | 7.59%  |
| 2025-03-31 | $14.98B  | 3.21%  |
| 2024-12-31 | $15.29B  | 8.27%  |
| 2024-09-30 | $14.75B  | 6.96%  |

**Analysis:** Revenue has been relatively stable. The profit margin has been consistently high, indicating strong profitability. Equity has been increasing gradually. ROE (Return on Equity) has fluctuated, with a recent dip in March 2025.

**7. Comprehensive Analysis (Summary)**

*   **Underperformance:** NOC has significantly underperformed the S&P 500.
*   **Mixed Signals:** Recent news and analyst opinions present a mixed picture. Some articles suggest undervaluation, while others highlight negative factors like a rating downgrade and insider selling. The MRI (Market Risk Indicator) recommends high investment, despite the historical underperformance, which requires further investigation.
*   **Price Trends:** Recent price action suggests short-term upward pressure but a longer-term downward trend. The price is hovering in a consolidation phase.
*   **Financial Stability:** Revenue and profit margins are generally strong, indicating a financially sound company.
*   **Conflicting Indicators:** A huge negative expected return of -158.8% is a major concern and contradicts the overall buy consensus of the analysts, pointing to a potential problem with the calculation.

**Overall Recommendation:**

Based on the provided data, a neutral to slightly bearish stance is warranted. While the company appears financially stable and some analysts see potential upside, the historical underperformance, mixed news, and significant negative expected return suggest caution. Further due diligence is required to understand the drivers behind the conflicting signals. In particular, understanding why the MRI gives a High Investment recommendation despite the other data points is crucial. Also, the negative expected return seems highly suspect and requires deeper analysis and verification.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.